Biotech company Amgen (NASDAQ: AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at the midpoint came in 1.7% above analysts’ estimates. Its non-GAAP profit of $5.29 per share was 11.9% above analysts’ consensus estimates.

Is now the time to buy AMGN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire. CEO Robert Bradway highlighted that 13 products delivered double-digit sales growth and 14 surpassed $1 billion in annual sales. The company also reported continued momentum in its rare disease and oncology segments, with notable performances from its biosimilars business. Management noted that sales growth was fueled by increased patient reach, new indication launches, and expanding access programs such as Amgen Now, particularly for Repatha. Murdo Gordon, Executive Vice President of Global Commercial Operations, emphasized expanded prescriber adoption and increased investment in priority brands as drivers of the quarter.

Looking ahead, Amgen’s guidance incorporates anticipated growth from its six key drivers, including further expansion of Repatha, Evenity, Tezspire, rare disease therapies, innovative oncology, and biosimilars. Management expects continued pipeline progress, particularly for Meritide, which is advancing through several late-stage studies targeting obesity, type 2 diabetes, and related conditions. CFO Peter Griffith emphasized, “We expect this growth in 2026 to more than offset anticipated declines from increased biosimilar competition and price declines for certain other products.” The company is also preparing for new product launches and further investments in manufacturing capacity to support future volume growth.

Key Insights from Management’s Remarks

Amgen management attributed the quarter’s performance to volume-driven growth in leading brands, new indication approvals, and disciplined investment in its pipeline and manufacturing.

• Repatha’s expanding role: The LDL cholesterol-lowering therapy saw accelerated adoption, driven by updated clinical trial data and broader prescriber engagement, particularly among primary care physicians following the Vesalius CV outcomes data. New patient access programs and expanded formulary coverage contributed to higher volumes.
• Rare disease therapies gain ground: Products like Eplisna benefited from new indications and regulatory approvals, including in IgG4-related disease and generalized myasthenia gravis, leading to increased uptake and broader prescriber base across specialties.
• Innovative oncology growth: The BiTE (bispecific T cell engager) platform, particularly Imdeltra for small cell lung cancer, achieved increased adoption, supported by recent full FDA approval and recognition in treatment guidelines as a second-line standard of care.
• Biosimilars momentum: Amgen’s biosimilar portfolio generated strong sales growth, with PavBlue (biosimilar to Eylea) gaining traction among retina specialists due to its ready-to-use syringe format and reliable supply chain. Management cited readiness for upcoming biosimilar launches.
• Pipeline advancement: Multiple late-stage programs, especially Meritide for obesity and type 2 diabetes, advanced through pivotal trials. Management underscored the differentiated potential of Meritide’s infrequent dosing regimen and efficacy, positioning it as a future growth engine.

Drivers of Future Performance

Amgen’s guidance reflects expectations for growth from its leading brands, new product launches, and ongoing pipeline investments, while recognizing competitive headwinds and evolving market dynamics.

• Meritide’s pivotal role: Management highlighted Meritide as a cornerstone of future growth, citing progress in Phase III trials targeting obesity, diabetes, and sleep apnea. Amgen believes its less frequent dosing (monthly or longer) and efficacy could differentiate it as a preferred therapy.
• Biosimilar competition and pricing: The company expects increased biosimilar competition to erode sales of legacy products like Prolia and Otezla, especially outside the U.S. Price declines in certain products and higher 340B program utilization are anticipated headwinds, partially offset by growth in newer therapies.
• Manufacturing and launch readiness: Amgen is increasing capital investments to scale manufacturing capacity for upcoming pipeline launches, particularly for Meritide. Management noted disciplined resource allocation and continued R&D spending to support late-stage programs and anticipated product introductions.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace of Meritide’s late-stage clinical trial enrollments and regulatory milestones, (2) the impact of biosimilar launches and pricing pressures on legacy product sales, and (3) adoption trends for new indications and geographies in rare disease and oncology franchises. Progress on manufacturing scale-up and execution on pipeline launches will also be key indicators of Amgen’s ability to sustain growth.

Amgen currently trades at $341.71, in line with $338.59 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.